Full Text PDF Similar Articles Mail to Author

¹Trakya Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Edirne
²Trakya Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Edirne
³Trakya Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, Edirne
⁴Trakya Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Edirne
⁵ Trakya Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Edirne Small cell carcinoma of the prostate is a very rare and aggressive tumor, which accounts for 0.5-2% of all prostate carcinomas. Signs and symptoms include obstructive, neurologic and constitutional symptoms like bone pain, abdominal pain, hematochezia, and hematuria later followed by symptoms of paraneoplastic syndromes like ectopic ACTH secretion and inappropriate ADH secretion and myasthenic syndrome. Approximately, 75% of patients have advanced disease at diagnosis. The small number of patients in the literature prevents a consensus for an optimal treatment option. Because small cell carcinomas of the prostate and lung are identical, treatment options are similar. Chemotherapy is the mainstay of the treatment. Cisplatin/etoposide chemotherapy is frequently used. External radiotherapy is used with combination chemotherapy for local control in the limited disease, as well as for palliation in extensive disease. This report describes management of a 76- year-old patient with an advanced stage small cell carcinoma of the prostate in light of the reviewed literature. Keywords : Chemotherapy; small cell carcinoma of the prostate; radiotherapy